Skip to main content

Advertisement

Table 3 Characteristics of individual patients

From: Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation

TACE
Patient Number Age Gender Etiology AFP # Tumors at Dx Size (cm) pre-op Within Milan Pre-TACE Growth rate (cm/mo.) Largest tumor dia by path Days to Transplant* Recur Time to Recur Reasons for TACE
A B
T1 61 M Cryptogenic 7254 1 6.3 N N/A 5 241 N   X  
T2 50 M HCV 27.9 1 3.5 Y 0.02 3.7 327 Y 14.5mo.   X
T3 53 M HCV 27.6 1 3.5 Y N/A 5 263 N    X
T4 54 M HCV 67 3 2.9, 1.6, 1 Y N/A 3 153 N    X
T5 58 M HCV 4 1 7.6 N 0 7.6 82 N   X  
T6 59 M HCV 4 2 3.1, 3.5 N 0.03 3.5 127 N   X  
T7 65 F HBV 667 1 2.5 Y 0.33 2.5 167 N    X
T8 68 F HCV 18 1 6 N N/A 4.7 174 N   X  
T9 57 M HCV 43 2 3.2, 1.8 N N/A 3.2 141 N   X  
T10 48 M HCV 40 4 3.5, 2.8, 2.5, 1.0 N 0.23 3.5 190 Y 6mo. X  
T11 49 M HCV 2000 1 3.5 Y 0.003 3.5 73 N    X
T12 53 M HCV 189 3 2.4, 0.6, 0.3 Y N/A 2.4 377 N    X
T13 54 M HCV 8 5 2.1, 1.5, 1.4, 1, .7 N 0 4 241 N   X  
T14 58 M HCV 188 1 6.3 N 0.12 5.5 345 Y 13mo. X  
T15 57 M HCV 3 3 2.8, 1.9, 1.3 Y N/A 2 263 Y 18.5mo.   X
T16 62 M HBV 20 2 1.7, 1.6 Y 0 2 153 N    X
  1. A = Downstage to achieve eligibility.
  2. B = Bridge to transplant.
  3. * = Days from HCC diagnosis to transplant.